Search Results
Aug 06, 2026, 06:59 ET Viatris Reports Second-Quarter 2026 Financial Results
Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced its second-quarter 2026 financial results.Executive Commentary"Our second-quarter
More news about: Viatris Inc.
Aug 04, 2026, 06:59 ET Viatris Announces Quarterly Dividend
Viatris Inc. (Nasdaq: VTRS) today announced that on August 3, 2026, its Board of Directors declared a quarterly dividend of $0.12 per share for each issued and outstanding share
More news about: Viatris Inc.
Jul 29, 2026, 06:59 ET Viatris Receives U.S. FDA Approval for Gwyn Lo™, a Once-Weekly Contraceptive Patch
Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has approved Gwyn Lo™ (norelgestromin and ethinyl estradiol
More news about: Viatris Inc.
Jul 01, 2026, 06:59 ET Viatris to Report Second-Quarter 2026 Financial Results on August 6, 2026
Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced it will report second-quarter 2026 financial results on Thursday, August 6, 2026. Company executives will
More news about: Viatris Inc.
Jun 29, 2026, 06:59 ET Viatris Announces Positive Top-Line Results from Phase 3 Study of VR-205 in Japanese Adults with Primary Immunoglobulin A Nephropathy
Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced positive top-line results from a Phase 3 clinical trial evaluating the efficacy and safety of VR-205 (targeted-release
More news about: Viatris Inc.
May 18, 2026, 08:00 ET U.S. FDA Accepts Viatris New Drug Application for Fast-Acting Meloxicam for the Treatment of Moderate-to-Severe Acute Pain
Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA)
More news about: Viatris Inc.
May 07, 2026, 16:30 ET Viatris to Present at the Bank of America Securities 2026 Healthcare Conference
Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the Company will present at the Bank of America Securities 2026 Healthcare Conference on Tuesday,
More news about: Viatris Inc.
May 07, 2026, 06:59 ET Viatris Reports First-Quarter 2026 Financial Results
Viatris Inc. (Nasdaq: VTRS) today announced its first-quarter 2026 financial results.
More news about: Viatris Inc.
May 05, 2026, 06:59 ET Viatris Announces Quarterly Dividend
Viatris Inc. (Nasdaq: VTRS) today announced that on May 4, 2026, its Board of Directors declared a quarterly dividend of $0.12 per share for each issued and outstanding share of
More news about: Viatris Inc.
May 04, 2026, 16:30 ET Viatris Announces Chief Financial Officer Transition
Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that Theodora "Doretta" Mistras, Chief Financial Officer, will depart the Company for a new professional
More news about: Viatris Inc.
May 01, 2026, 06:59 ET Viatris Announces Several Data Presentations on Investigational Low-Dose Estrogen Combined Hormonal Contraceptive Weekly Patch at the 2026 American College of Obstetricians and Gynecologists Annual Clinical & Scientific Meeting
Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that six abstracts on its investigational low-dose estrogen combined hormonal contraceptive (CHC) weekly
More news about: Viatris Inc.
Apr 13, 2026, 06:59 ET Viatris to Report First Quarter 2026 Financial Results on May 7, 2026
Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced it will report first quarter 2026 financial results on Thursday, May 7, 2026. Company executives will
More news about: Viatris Inc.
Apr 10, 2026, 06:59 ET Viatris Announces Multiple Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting
Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that four abstracts will be presented at the American Society of Cataract and Refractive Surgery (ASCRS)
More news about: Viatris Inc.
Mar 23, 2026, 06:59 ET Viatris Advances Innovative Portfolio with Approval of Effexor® in Japan for Adults with Generalized Anxiety Disorder (GAD)
Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Effexor® SR 37.5 mg
More news about: Viatris Inc.
Mar 19, 2026, 08:30 ET Viatris to Outline its Vision for Sustained Revenue and Earnings Growth Through 2030
Viatris Inc. (Nasdaq: VTRS) will host its Investor Event today, where members of the executive leadership team will outline the Company's strategic vision, key drivers and financial
More news about: Viatris Inc.
Feb 26, 2026, 06:59 ET Viatris Reports Fourth-Quarter and Full-Year 2025 Financial Results
Viatris Inc. (Nasdaq: VTRS) today announced robust financial results for the fourth quarter and full year 2025. The Company also announced it has completed its enterprise-wide
More news about: Viatris Inc.
Feb 26, 2026, 06:55 ET Viatris Maintains Dividend Policy for 2026 and Announces Quarterly Dividend
Viatris Inc. (Nasdaq: VTRS) today announced that on February 23, 2026, its Board of Directors approved a 2026 dividend policy of 48 cents ($0.48) per share and declared a quarterly
More news about: Viatris Inc.
Feb 25, 2026, 06:59 ET FDA Accepts Viatris Supplemental New Drug Application for MR-141 (Phentolamine Ophthalmic Solution 0.75%) for the Treatment of Presbyopia
Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application
More news about: Viatris Inc.
Feb 03, 2026, 16:34 ET Viatris to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026, and Host Investor Event on March 19, 2026
Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced it will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026. Company
More news about: Viatris Inc.
Feb 03, 2026, 08:30 ET Viatris Appoints Matthew J. Maletta as Chief Legal Officer
Viatris Inc. (Nasdaq: VTRS) announced today that Matthew J. Maletta has been appointed Chief Legal Officer (CLO), effective February 9, 2026. The appointment follows the transition
More news about: Viatris Inc.
Jan 20, 2026, 06:59 ET Viatris Expands Innovative Portfolio in Cardiovascular Diseases with the Company's First Launch of Inpefa® (Sotagliflozin) for the Treatment of Heart Failure
Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced the launch of Inpefa® (sotagliflozin) in the United Arab Emirates (UAE), the first country
More news about: Viatris Inc.
Jan 08, 2026, 09:05 ET Viatris Appoints Lara Ramsburg as Chief People and Corporate Affairs Officer
Viatris Inc. (Nasdaq: VTRS) announced today that Lara Ramsburg has been appointed Chief People and Corporate Affairs Officer. As part of Viatris' ongoing transformation efforts,
More news about: Viatris Inc.
Dec 18, 2025, 06:59 ET Viatris Provides Pipeline Update on Four Regulatory Milestones
Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced four recent regulatory milestones spanning across all stages of its global pipeline:Octreotide
More news about: Viatris Inc.
Dec 17, 2025, 06:59 ET Viatris to Present at the 44th Annual J.P. Morgan Healthcare Conference
Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the Company will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco
More news about: Viatris Inc.
Dec 06, 2025, 09:00 ET Viatris Announces Agreement to Monetize its Equity Stake in Biocon Biologics Limited
Viatris Inc. (Nasdaq: VTRS) today announced that it has entered into definitive agreements with Biocon Limited ("Biocon") for the sale of Viatris' equity stake in Biocon Biologics
More news about: Viatris Inc.